BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Johnson & Johnson Tops Profit Expectations, Lifts Outlook Following Price Increases To Start the Year

This week, Big Pharma giant Johnson & Johnson posted second-quarter earnings that surpassed Wall Street expectations. The strong earnings report follows the company hiking prices on at least 28 prescription drugs so far this year. Johnson & Johnson raised their full year sales guidance to between $100.8 billion to $101.4 billion, an increase from the previous quarter. Johnson & Johnson has consistently topped earnings expectations for years, while continuing to increase prices across its portfolio.

Get a full recap of Johnson & Johnson’s latest earnings here:

Johnson & Johnson

• Johnson & Johnson reported second quarter earnings that topped Wall Street expectations.
• In the second quarter, the Big Pharma company’s oncology drug, Darzalex, brought in sales of $4.2 billion.
• The company’s psoriasis drug, Tremfya, brought in $2 billion in sales, compared to estimates of $1.74 billion.
• Johnson & Johnson now expects full-year sales of $100.8 billion to $101.4 billion.

Johnson & Johnson’s earnings reflect a continuing pattern of egregious pricing practices across its top-selling blockbuster drugs.

Johnson & Johnson

• Johnson & Johnson has hiked prices on 28 prescription drugs so far in 2026, including a five percent increase on psoriasis drug Stelara.
• Johnson & Johnson hiked prices on 30 prescription drugs in 2025, including a 5.5 percent increase on multiple myeloma drug Darzalex and a 4.7 percent increase on psoriasis drug Stelara. 
• Johnson & Johnson engaged in 34 price hikes in 2024, including a 4.8 percent increase on Darzalex, and five percent increases on Erleada and Stelara.
• According to a December 2024 ICER report, price hikes that were unsupported by new clinical evidence on the multiple myeloma drug Darzalex led to additional consumer spending of $190 million.
• Johnson & Johnson also engaged in 36 price hikes in 2023, including a 4.5 percent increase on Darzalex, a five percent increase on Erleada and a 4 percent increase on Stelara.
• Spending on the company’s blockbuster cancer drug Imbruvica is expected to exceed $41 billion between 2027 and 2036, thanks to an anti-competitive patent scheme that extended a monopoly on the high-priced cancer drug by more than nine years. Imbruvica costs an eye-popping $180,000 per year.

Stay tuned as we continue to monitor second quarter earnings calls from brand name drug companies in the coming weeks.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.